enGene Therapeutics Clinical Trial Data
enGene Therapeutics announced results from the pivotal Cohort 1 of its Phase 2 LEGEND trial evaluating detalimogene in BCG-unresponsive non-muscle invasive bladder cancer. The company also reached alignment with the FDA on key components for its planned Biologics License Application (BLA) submission.
- Counterparty
- FDA